<clinical_study>
<study_id>
<org_name>
  GSK
</org_name>
<org_full_name>
  GlaxoSmithKline
</org_full_name>
<org_study_id>
  VRX-RET-E22-303
</org_study_id>
<nct_id>
  NCT00310375
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
</textblock>
</brief_title>
<official_title>
<textblock>
  A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  GlaxoSmithKline
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study.  The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-301 trial.  Patients who have completed the VRX-RET-E22-301 trial and who meet inclusion and exclusion criteria will be treated with 600-1200 mg/day of retigabine as an adjunct therapy to their current antiepileptic drugs (AEDs) or vagal nerve stimulation.  Treatment will be continued until retigabine is commercially available, or until the program is discontinued.  Patients will be recruited from 45-50 sites in the United States, Canada, Mexico, Brazil, and Argentina.  The safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures will be evaluated.  In addition, the efficacy of long-term treatment with retigabine and patient quality of life will be assessed.
</textblock>
</detailed_descr>
<status_block>
<status>
  Active, not recruiting
</status>
<date>
  2011-06
</date>
</status_block>
<start_date>
<date>
  2006-05
</date>
</start_date>
<last_follow_up_date
 type="Anticipated"
>
<date>
  2012-11
</date>
</last_follow_up_date>
<primary_compl_date
 type="Anticipated"
>
<date>
  2012-11
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Non-Randomized
</design>
<design>
  Open Label
</design>
<design>
  Single Group Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  1
</number_of_arms>
<primary_outcome>
<measure>
  Percentage change in the monthly seizure rate from the baseline phase to the open-label treatment phase.
</measure>
<time_frame>
  Frequency rates to be determined at end of the open-label treatment phase
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Reports of adverse events
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Results of vital signs
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Weight
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Clinical laboratory evaluations
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  12-lead ECG
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Post-void residual bladder ultrasounds
</measure>
<time_frame>
  At selected study visits
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  181
</enrollment>
<condition>
  Epilepsies, Partial
</condition>
<arm_group>
<arm_group_label>
  Ezogabine: USAN Retigabine: INN
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Ezogabine: USAN  Retigabine: INN
</primary_name>
<description>
<textblock>
  Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet.  Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day.  The duration will be until the trial concludes or the patient leaves the trial.
</textblock>
</description>
<arm_group_label>
  Ezogabine: USAN Retigabine: INN
</arm_group_label>
<other_name>
  GKE-841
</other_name>
<other_name>
  D-23129
</other_name>
<other_name>
  GW582892X
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Patient has successfully completed the Maintenance and Transition phases of Study VRX-RET-E22-301 for the treatment of partial-onset seizures
  - Patient is expected to benefit from participation in the study in the opinion of the Investigator.
 
  Exclusion Criteria:
    - Patient meets any of the withdrawal criteria in the previous VRX-RET-E22-301 study or is experiencing an ongoing serious adverse event.
  - Patient is receiving any investigational drug or using any experimental device in addition to Retigabine for treatment of epilepsy or any other medical condition.
  - Patient has any other condition that would prevent compliance with the study procedures or proper reporting of adverse events.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  75 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  GSK Clinical Trials
</name>
<affiliation>
<agency>
  GlaxoSmithKline
</agency>
</affiliation>
</investigator>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<location>
<facility>
<name>
  North Alabama Neuroscience Research Associates
</name>
<address>
<city>
  Huntsville
</city>
<state>
  Alabama
</state>
<zip>
  35801
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jennifer Perry
</name>
<phone>
  256-533-3552
</phone>
<phone_ext>
</phone_ext>
<email>
  jperry@clinicforneurology.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  Neurology Clinic
</name>
<address>
<city>
  Northport
</city>
<state>
  Alabama
</state>
<zip>
  35476
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Maryann Hannah
</name>
<phone>
  205-333-2626
</phone>
<phone_ext>
</phone_ext>
<email>
  ncpc1325@bellsouth.net
</email>
</contact>
</location>
<location>
<facility>
<name>
  University of Alabama -- Department of Neurology/Epilepsy Center
</name>
<address>
<city>
  Birmingham
</city>
<state>
  Alabama
</state>
<zip>
  35294
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  R. Edward Faught, MD
</name>
<phone>
  205-934-3866
</phone>
<phone_ext>
</phone_ext>
<email>
  faught@uab.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Barrow Neurological Institute
</name>
<address>
<city>
  Phoenix
</city>
<state>
  Arizona
</state>
<zip>
  85013
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Nicole Hank
</name>
<phone>
  602-406-6251
</phone>
<phone_ext>
</phone_ext>
<email>
  nicole.hank@chw.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Clinical Trials Inc.
</name>
<address>
<city>
  Little rock
</city>
<state>
  Arkansas
</state>
<zip>
  72205
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Dusty Hollis-Holderfield
</name>
<phone>
  501-227-6179
</phone>
<phone_ext>
</phone_ext>
<email>
  dholderfield@clinicaltrialsinc.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  West Los Angeles VA Healthcare Center
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
  90073
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Kimberly Panizzon
</name>
<phone>
  818-744-8252
</phone>
<phone_ext>
</phone_ext>
<email>
  kpanizzon@yahoo.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  University of Southern California -- Keck School of Medicine
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
  90033
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Susan Milstein
</name>
<phone>
  323-224-5555
</phone>
<phone_ext>
</phone_ext>
<email>
  smilstei@usc.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  UCSD Thornton Hospital
</name>
<address>
<city>
  La Jolla
</city>
<state>
  California
</state>
<zip>
  92037
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Evelyn S Tecoma, MD, PhD
</name>
<phone>
  858-657-6080
</phone>
<phone_ext>
</phone_ext>
<email>
  etecoma@ucsd.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Delta Waves
</name>
<address>
<city>
  Colorado Springs
</city>
<state>
  Colorado
</state>
<zip>
  80918
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Steven H Spillers, MD
</name>
<phone>
  719-955-6481
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  University of Colorado Department Of Neurology
</name>
<address>
<city>
  Denver
</city>
<state>
  Colorado
</state>
<zip>
  80010
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
</location>
<location>
<facility>
<name>
  University of Miami
</name>
<address>
<city>
  Miami
</city>
<state>
  Florida
</state>
<zip>
  33136
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Marinellie Vega
</name>
<phone>
  305-243-5944
</phone>
<phone_ext>
  8
</phone_ext>
<email>
  mvega@epiworld.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  Lovelace Scientific Resources
</name>
<address>
<city>
  Sarasota
</city>
<state>
  Florida
</state>
<zip>
  34233
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Denise Dorman
</name>
<phone>
  941-379-8810
</phone>
<phone_ext>
</phone_ext>
<email>
  ddorman@lrri.org
</email>
</contact>
</location>
<location>
<facility>
<name>
  University of Florida -- Shands Jacksonville
</name>
<address>
<city>
  Jacksonville
</city>
<state>
  Florida
</state>
<zip>
  32209
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Marc Lojacono
</name>
<phone>
  904-244-9468
</phone>
<phone_ext>
</phone_ext>
<email>
  marc.lojacono@jax.ufl.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  McFarland Clinic
</name>
<address>
<city>
  Ames
</city>
<state>
  Iowa
</state>
<zip>
  50010
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Jolene Frette
</name>
<phone>
  515-239-6868
</phone>
<phone_ext>
</phone_ext>
<email>
  jfrette@mcfarlandclinic.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  University of Kentucky
</name>
<address>
<city>
  Lexington
</city>
<state>
  Kentucky
</state>
<zip>
  40536
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Yaira Garzon
</name>
<phone>
  859-323-5406
</phone>
<phone_ext>
</phone_ext>
<email>
  yaira.garzon@uky.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Mid-Atlantic Epilepsy and Sleep Center
</name>
<address>
<city>
  Bethesda
</city>
<state>
  Maryland
</state>
<zip>
  20817
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Pavel Klein, MD
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
  kleinp@epilepsydc.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  Henry Ford Hospital
</name>
<address>
<city>
  Detroit
</city>
<state>
  Michigan
</state>
<zip>
  48202
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Sharon McCarthy
</name>
<phone>
  313-916-2214
</phone>
<phone_ext>
</phone_ext>
<email>
  sharonm@neuro.hfh.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Minnesota Epilepsy Group, P.A.
</name>
<address>
<city>
  St. Paul
</city>
<state>
  Minnesota
</state>
<zip>
  55102
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Gail Sherman
</name>
<phone>
  651-241-5289
</phone>
<phone_ext>
</phone_ext>
<email>
  gsherman@mnepilepsy.net
</email>
</contact>
</location>
<location>
<facility>
<name>
  The Comprehensive Epilepsy Care Center for Children and Adults
</name>
<address>
<city>
  Chesterfield
</city>
<state>
  Missouri
</state>
<zip>
  63017
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Cecelia Fields
</name>
<phone>
  314-453-9300
</phone>
<phone_ext>
  35
</phone_ext>
<email>
  werosenfeld@msn.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  Beth Israel Medical Center
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
  10003
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jeffrey Cohen, MD, PhD
</name>
<phone>
  212-844-6111
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Asheville Neurology Specialists
</name>
<address>
<city>
  Asheville
</city>
<state>
  North Carolina
</state>
<zip>
  28801
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Susan Woodard, CCRC
</name>
<phone>
  828-210-9308
</phone>
<phone_ext>
</phone_ext>
<email>
  swoodard@ashneuro.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  Medical University of Ohio at Toledo
</name>
<address>
<city>
  Toledo
</city>
<state>
  Ohio
</state>
<zip>
  43614
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Andrea Korsnack, RN, CNRN
</name>
<phone>
  419-383-3801
</phone>
<phone_ext>
</phone_ext>
<email>
  akorsnack@mco.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Oregon Neurology PC
</name>
<address>
<city>
  Tualatin
</city>
<state>
  Oregon
</state>
<zip>
  97062
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Paul R Ash, MD
</name>
<phone>
  503-692-2850
</phone>
<phone_ext>
</phone_ext>
<email>
  ashpr@comcast.net
</email>
</contact>
</location>
<location>
<facility>
<name>
  Milton S. Hershey Medical Center
</name>
<address>
<city>
  Hershey
</city>
<state>
  Pennsylvania
</state>
<zip>
  17033
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Paul McCabe
</name>
<phone>
  717-531-5600
</phone>
<phone_ext>
</phone_ext>
<email>
  pmccabe@psu.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Vanderbilt University Medical Center
</name>
<address>
<city>
  Nashville
</city>
<state>
  Tennessee
</state>
<zip>
  37212
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Diana Jackson
</name>
<phone>
  615-936-0209
</phone>
<phone_ext>
</phone_ext>
<email>
  diana.jackson@vanderbilt.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Neurological Clinic of Texas
</name>
<address>
<city>
  Dallas
</city>
<state>
  Texas
</state>
<zip>
  75230
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Robert F Leroy
</name>
<phone>
  972-566-7690
</phone>
<phone_ext>
</phone_ext>
<email>
  rfleroy@airmail.net
</email>
</contact>
</location>
<location>
<facility>
<name>
  Memorial  Hermann Hospital
</name>
<address>
<city>
  Houston
</city>
<state>
  Texas
</state>
<zip>
  77030
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jeremy D Slater, MD
</name>
<phone>
  713-500-7106
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Medical City Dallas Hospital
</name>
<address>
<city>
  Dallas
</city>
<state>
  Texas
</state>
<zip>
  75230
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
</location>
<location>
<facility>
<name>
  University of Virginia Comprehensive Epilepsy Program
</name>
<address>
<city>
  Charlottesville
</city>
<state>
  Virginia
</state>
<zip>
  22903
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Nathan B Fountain, MD
</name>
<phone>
  434-243-6281
</phone>
<phone_ext>
</phone_ext>
<email>
  nbf2p@virginia.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Virginia Commonwealth University Medical Center
</name>
<address>
<city>
  Richmond
</city>
<state>
  Virginia
</state>
<zip>
  23298
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Alan R Towne, MD
</name>
<phone>
  804-828-9869
</phone>
<phone_ext>
</phone_ext>
<email>
  atowne@hsc.vcu.edu
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital General de Agudos &quot;Dr. J.M. Ramos Mejia&quot;
</name>
<address>
<city>
  Capital Federal
</city>
<state>
  CBA
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Silvia Kochen
</name>
<phone>
  54-11-49326101
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital General de Agudos &quot;Dr. Teodoro Alvarez&quot;
</name>
<address>
<city>
  Capital Federal
</city>
<state>
  CBA
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Veronica Campanille
</name>
<phone>
  54-11-54009507
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Italiano de Buenos Aires
</name>
<address>
<city>
  Capital Federal
</city>
<state>
  CBA
</state>
<zip>
  C1181ACH
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Stella Maris Valiensi
</name>
<phone>
  54-11-49590322
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Privado Centro Medico de Cordoba
</name>
<address>
<city>
  Cordoba
</city>
<state>
  CRD
</state>
<zip>
  X5016KEH
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Maria Jesus Frias
</name>
<phone>
  54-351-4688216
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Sanatorio del Salvador II
</name>
<address>
<city>
  Cordoba
</city>
<state>
  CRD
</state>
<zip>
  5000
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Leonardo Kremer
</name>
<phone>
  54-351-4528888
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Fundacion Lennox
</name>
<address>
<city>
  Cordoba
</city>
<state>
  CRD
</state>
<zip>
  5000
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Roberto Giobellina
</name>
<phone>
  54-351-4235128
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Universitario Prof Edgard Santos -- UFBA
</name>
<address>
<city>
  Salvador
</city>
<state>
  BA
</state>
<zip>
  40110-060
</zip>
<country>
  Brazil
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Marielza  Fernan Veiga
</name>
<phone>
  55-71-3339-6253
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Sao Paulo -- Escola Paulista de Medicina -- UNIFESP
</name>
<address>
<city>
  Sao Paulo
</city>
<state>
  SP
</state>
<zip>
  04024 002
</zip>
<country>
  Brazil
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Elza Marcia Tar Yacubian
</name>
<phone>
  55-11-5576-4541
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital das Clinicas da Fac de Medicina de Sao Paulo
</name>
<address>
<city>
  Sao Paulo
</city>
<state>
  SP
</state>
<zip>
  05403-900
</zip>
<country>
  Brazil
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Maria Luiza Gir De Manreza
</name>
<phone>
  55-11-3069-6106
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital das Clinicas de Ribeirao Preto -- Universidade de Sa Neurologia
</name>
<address>
<city>
  Ribeirao Preto
</city>
<state>
  SP
</state>
<zip>
  14048-900
</zip>
<country>
  Brazil
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Americo Ceiki Sakamoto
</name>
<phone>
  55-16-633-9000
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Foothills Medical Center
</name>
<address>
<city>
  Calgary
</city>
<state>
  Alberta
</state>
<zip>
  T2N 2T9
</zip>
<country>
  Canada
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Neelan Pillay
</name>
<phone>
  403-944-4556
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Glenrose Rehabilitation Center
</name>
<address>
<city>
  Edmonton
</city>
<state>
  Alberta
</state>
<zip>
  T5G 0B7
</zip>
<country>
  Canada
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Corinne McMillan, M.S.
</name>
<phone>
  780-735-8886
</phone>
<phone_ext>
</phone_ext>
<email>
  corinnemcmillan@cha.ab.ca
</email>
</contact>
</location>
<location>
<facility>
<name>
  Health Sciences Centre
</name>
<address>
<city>
  St. John&apos;s
</city>
<state>
  Newfoundland and Labrador
</state>
<zip>
  A1B 3V6
</zip>
<country>
  Canada
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Abayomi Ogunyemi
</name>
<phone>
  709-777-6585
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CHUM -- H&#244;pital Notre-Dame
</name>
<address>
<city>
  Montr&#233;al
</city>
<state>
  Quebec
</state>
<zip>
  H2L 4M1
</zip>
<country>
  Canada
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Patrick Cossette
</name>
<phone>
  514-890-8000
</phone>
<phone_ext>
  25523
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CIF BIOTEC, Medica Sur
</name>
<address>
<city>
  Tlalpan
</city>
<state>
  DF
</state>
<zip>
  14050
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Gloria Llamosa-Garcia Velazquez
</name>
<phone>
  52-55-54240110
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Centro Medico
</name>
<address>
<city>
  Mexico
</city>
<state>
  DF
</state>
<zip>
  03229
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Lilia Nunez Orozco
</name>
<phone>
  52-55-52005003
</phone>
<phone_ext>
  4292
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital de Psiquiatria San Fernando, IMSS
</name>
<address>
<city>
  Mexico
</city>
<state>
  DF
</state>
<zip>
  14050
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Marcela Perez-Arreola
</name>
<phone>
  52-55-56060391
</phone>
<phone_ext>
</phone_ext>
<email>
  marcelaperezarreola@prodigy.net
</email>
</contact>
</location>
<location>
<facility>
<name>
  Instituto Nacional de Neurologia y Neurocirugia
</name>
<address>
<city>
  La Fama
</city>
<state>
  DF
</state>
<zip>
  42690
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Marie-Catherine Woehrlen, MD
</name>
<phone>
  52-55-56063822
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Antiguo Hospital Civil de Guadalajara
</name>
<address>
<city>
  Guadalajara
</city>
<state>
  Jalisco
</state>
<zip>
  44280
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Jose L Ruiz-Sandoval, Dr.
</name>
<phone>
  52 33 36134016
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital y Clinica OCA S.A. de C.V.
</name>
<address>
<city>
  Monterrey
</city>
<state>
  Nuevo Leon
</state>
<zip>
  64000
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Albino Contreras Milian, MD
</name>
<phone>
  +52 (81) 8346-1160
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Central Dr. Ignacio Morones Prieto
</name>
<address>
<city>
  San Luis Potosi
</city>
<state>
  SLP
</state>
<zip>
  78250
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Idelfonso Rodriguez
</name>
<phone>
  52-44-48176692
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  Epilepsy
</keyword>
<keyword>
  Partial Seizures
</keyword>
<keyword>
  Potassium Channels
</keyword>
<keyword>
  Anticonvulsant
</keyword>
<keyword>
  Complex Partial Seizures
</keyword>
<initial_release_date>
  2006-03-30
</initial_release_date>
<last_release_date>
2011-09-26 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
